Aa
Aa
A
A
A
Close
Avatar universal

MSers 50 & 0ver...what do you think?

In the latest edition of Narcoms Now, Dr. Robert Fox, practicing neurologist at the Cleveland Clinic, posted this comment on page 17 of the magazine:  "Another tricky area with DMTs (or DMDs as we call them) is how to know when someone doesn't need them anymore. MS inflammation typically quiets down as patients get older (i.e. over 50 years), and many patients will "graduate" from needing DMTs at some point - but when?"

So by his comment does he mean inflammation dies down, because the disease progression slows down when we are 50 and over? If so, I will stop paying the enormous cost of my DMD. And also, what does that mean for the disability progression?  I sent Narcoms an email questioning the statement, but still have not received a response.

Have any of  you heard this said before? That basically the older you get the more the inflammation slows down. Have your neurologists said anything regarding this possibility? This is news to me and I am knocking on the door of the 50 threshold, so maybe that will be one good thing about turning 50!

What do you think he means by this comment? And what has been your experience?  
3 Responses
Sort by: Helpful Oldest Newest
667078 tn?1316000935
I have heard this statement before. Each case of MS is unique. I have a very slow progressing MS I have had since my first attack in 1965. In my case my MS seems to have leveled off. My MRIs are identical to each other even years apart. I have even had lesions disappear on my MRIs. I am just 50.

I am not on a DMD since I also have Cancer.

Alex
Helpful - 0
1831849 tn?1383228392
I was diagnosed @51 in conjunction with a major relapse. It was determined at that time that A) I have had MS since I was 31 and B) I now have SPMS. Since my DX I have been receiving Tysabri.

I have not had a relapse since. Who knows whether it's the slowing down of the MS inflammation, the Tysabri or none of the above (it was 18 years between my first 2 major relapses and another 2 years before my third).

At this point I'm not sure I care why my MS seems to be quiet. I have a handful of everyday, permanent symptoms that are fairly well managed with meds. I'm not ready to forsake DMD's at this point to test a hypothesis :-)

Kyle
Helpful - 0
987762 tn?1671273328
COMMUNITY LEADER
Good morning,

I believe what he was talking about is the progression from RRMS to SPMS and the "ie over 50 years old", being the oldest MSer age group, which is when that is more likely because of the number of years (decades) that they've had MS for.

With progression into SPMS, the pwMS no longer have the relapses and recovery stages but they continue to decline at a much slower rate and with a less obvious pattern to it. DMD's are targetting the relapse rates a pwMS has, and if they arn't relapsing, then the DMD's are not going to be working for them anymore.

I dont' think he was inferring that 50 is a golden age or anything, transfering from RRMS to SPMS is as individual as the disease but if its going to happen, its more likely (or on average) going to be after your 50. Graduating as he puts it, is not really a good thing if there isn't an alternative medication available.

Cheers.........JJ  



  
Helpful - 0
Have an Answer?

You are reading content posted in the Multiple Sclerosis Community

Top Neurology Answerers
987762 tn?1671273328
Australia
5265383 tn?1669040108
ON
1756321 tn?1547095325
Queensland, Australia
1780921 tn?1499301793
Queen Creek, AZ
Learn About Top Answerers
Didn't find the answer you were looking for?
Ask a question
Popular Resources
Find out how beta-blocker eye drops show promising results for acute migraine relief.
In this special Missouri Medicine report, doctors examine advances in diagnosis and treatment of this devastating and costly neurodegenerative disease.
Here are 12 simple – and fun! – ways to boost your brainpower.
Discover some of the causes of dizziness and how to treat it.
Discover the common causes of headaches and how to treat headache pain.
Two of the largest studies on Alzheimer’s have yielded new clues about the disease